PBMs Hinder Access To Generics And Biosimilars, Finds FTC’s Investigation
The Biosimilars Forum And AAM Commend FTC, While PBM Association Hits Back
An FTC report has shown evidence of “troubling rebating practices” between pharma companies and PBMs, lowering access to generics and biosimilars. While off-patent groups commended the agency, the PBM association said the report falls short of being definitive or fact-based.
